Juliano, Rebecca A.

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 3,317

Effects of Icosapent Ethyl on Total Ischemic Events

Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · Journal of the American College of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 259

Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Bhatt, D. L., Steg, P. G., Brinton, E. A., Jacobson, T. A., Miller, M., Tardif, J., Ketchum, S. B., Doyle, R. T., Murphy, S. A., Soni, P. N., et al. (2017) · Clinical Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 183

REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States

Bhatt, D. L., Miller, M., Brinton, E. A., Jacobson, T. A., Steg, P. G., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2020) · Circulation

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 136

Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies

Olshansky, B., Chung, M. K., Budoff, M. J., Philip, S., Jiao, L., Doyle, Jr., Copland, C., Giaquinto, A., Juliano, R. A., & Bhatt, D. L. (2020) · European Heart Journal Supplements

Fatty Acid Research and HealthStatistical Methods in Clinical Trials

Cited by 103

EPA and DHA containing phospholipids have contrasting effects on membrane structure

Sherratt, S. C. R., Juliano, R. A., Copland, C., Bhatt, D. L., Libby, P., & Mason, R. P. (2021) · Journal of Lipid Research

Fatty Acid Research and HealthLipid Membrane Structure and Behavior

Cited by 92

Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction

Gaba, P., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2022) · Journal of the American College of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 61

Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses

Peterson, B. E., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2021) · Circulation

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 57

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies

Ballantyne, C. M., Bays, H. E., Philip, S., Doyle, R. T., Braeckman, R. A., Stirtan, W. G., Soni, P. N., & Juliano, R. A. (2016) · Atherosclerosis

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 52

Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies

Cummings, B. B., Joing, M. P., Bouchard, P. R., Milton, M. N., Moesta, P. F., Ramanan, V., Lane, A., Hirman, J., Trauger, J. W., Maratos-Flier, E., et al. (2025) · The Lancet

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 49

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies

Ballantyne, C. M., Bays, H. E., Braeckman, R. A., Philip, S., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2016) · Journal of Clinical Lipidology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 47

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

Ballantyne, C. M., Braeckman, R. A., Bays, H. E., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2015) · Journal of Clinical Lipidology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 46

Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies

Bays, H. E., Ballantyne, C. M., Doyle, R. T., Juliano, R. A., & Philip, S. (2016) · Prostaglandins & Other Lipid Mediators

Fatty Acid Research and HealthLipid metabolism and disorders

Cited by 43

Cardiovascular benefits of icosapent ethyl in patients with and without atrial fibrillation in REDUCE-IT

Olshansky, B., Bhatt, D. L., Miller, M., Steg, P. G., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., et al. (2023) · Journal of the American Heart Association

Fatty Acid Research and HealthAtrial Fibrillation Management and Outcomes

Cited by 29

REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results

Olshansky, B., Bhatt, D. L., Miller, M., Steg, P. G., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle Jr, R. T., Juliano, R. A., Jiao, L., et al. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 25

Lipid effects of icosapent ethyl in women with diabetes mellitus and persistent high triglycerides on statin treatment: ANCHOR trial subanalysis

Brinton, E. A., Ballantyne, C. M., Guyton, J. R., Philip, S., Doyle, R. T., Juliano, R. A., & Mosca, L. (2018) · Journal of Women's Health

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 13

Reply

Bhatt, D. L., Steg, P. G., Miller, M., Juliano, R. A., & Ballantyne, C. M. (2019) · Journal of the American College of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 11